Redx Pharma Plc
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.redxpharma.com
Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Redx Pharma Plc
- Target Recruit Count
- 48
- Registration Number
- NCT05570058
- Locations
- 🇦🇹
Medical University of Vienna, Wien, Austria
🇧🇪E PNE UZ Leuven, Leuven, Belgium
🇧🇪CHU De Liège, Liège, Belgium
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
- Conditions
- InflammationIdiopathic Pulmonary FibrosisLiver DiseasesKidney DiseasesNon-alcoholic SteatohepatitisFibrosis
- Interventions
- Drug: RXC007 Matching Placebo
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Redx Pharma Plc
- Target Recruit Count
- 90
- Registration Number
- NCT04931147
- Locations
- 🇬🇧
Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, Mid Glamorgan, United Kingdom
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Redx Pharma Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT04907851
- Locations
- 🇦🇺
Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺The Alfred Hospital - Alfred Health, Melbourne, Victoria, Australia
🇬🇧Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Redx Pharma Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT04907539
- Locations
- 🇺🇸
Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸Community Health Network Cancer Center North - Community Hospital Network, Indianapolis, Indiana, United States
🇺🇸OptumCare Cancer Care, Las Vegas, Nevada, United States
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Redx Pharma Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT03447470
- Locations
- 🇬🇧
Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, United Kingdom
🇬🇧Guys Hospital, London, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom